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and high TRM rate has to be improved by preemptive DLI
therapy and better supportive care.Table 1
Association of Expression of Myeloid Antigens with Survival in Adult ALL
Short Survival CD13 CD33 CD13 or 33 or 117
RFS24months 44% vs 16%,
P ¼ .014
35% vs 13%,
P ¼ .044
57% vs 27%,
P ¼ .018
OS 24 months 50% vs 16%,
P ¼ .006
35% vs 16%,
P ¼ .095
64% vs 28%,
P ¼ .006
OS 60 months 34% vs 8%,
P ¼ .979
24% vs 17%,
P ¼ .591
46% vs 23%,
P ¼ .138222
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Allogeneic hematopoietic cell transplantation (HCT) is the
only curative therapy for Ph+ ALL. Reduced intensity condi-
tioning (RIC) has been explored to limit transplant related
mortality (TRM) while allowing engraftment and the graft-
versus- leukemia effect, perhaps enhanced by use of TKI and
monitoring for MRD by cytogenetic and molecular tech-
niques. Data on TKI and pre-transplant MRD on RIC HCT
outcomes are lacking.
We analyzed 197 adults with Ph+ ALL in CR1 reported to
CIBMTR between 2001-2009 and collected data on pre- and
post-HCT TKI administration and pre-transplant MRD. Sixty-
seven patients receiving RIC were matched with 130 mye-
loablative (MA) HCT recipients (matched for age, donor type
and transplant year). Median age in RIC (54 years) was older
than MA (50 years). The RIC group had more frequent pre-
HCT fungal infections and a longer time from diagnosis to CR.
Themajority in both groups received TKI pre-transplant (RIC:
76% vs MA: 78%) while only 31% (RIC) and 17% (MA) received
TKI post-transplant. Most patients had MRD monitored pre-
HCT by cytogenetic testing (89%) or BCR/ABL PCR (64%).
TRM at 1 year was almost 3-fold lower following RIC
compared to MA HCT (13% vs 36%; P < .001). In contrast, the
3-yr relapse rate was higher after RIC HCT (49% vs 28%; P ¼
.058) resulting in similar 3 year overall survival (OS) and
disease-free survival (DFS) following RIC and MA allograft
(OS: 39% vs 35%, P ¼ .62; DFS: 26% vs 28%, P ¼ .75). In
multivariate analysis, RIC was associated with 2 fold
increased relapse risk, but had no signiﬁcant impact on
survival. Post-transplant TKI use and younger age (< 40
years) associated with signiﬁcantly lower TRM and improved
OS. Probability of grade II-IV acute GVHDwas 30% and 47% in
RIC and MA groups respectively (P ¼ .014), while condi-
tioning intensity did not alter the incidence of chronic GVHD.
Pre-transplant TKI therapy might inﬂuence clearance of
MRD pre-HCT and risk of relapse. Among 153 patients who
received pre-HCT TKI, complete molecular and cytogenetic
remission was 22% (RIC) and 26% (MA); similar to pre-HCT
MRD status of patients without TKI (RIC 19%; MA 18%).
Importantly, in adjusted multivariate analysis, positive BCR/
ABL pre-HCT was strongly associated with increased relapse
(HR 2.72; P¼ .003) anduse of pre-HCTTKIwas associatedwith
a2-fold reduction in relapse (HR0.49;P¼.003).MRDpositivity
or pre-transplant TKI had no signiﬁcant inﬂuence on survival.
In this matched case-control study, we demonstrated that
RIC HCT yields similar survival of adults with Ph+ALL in CR1
compared to MA allografts. Importantly, relapse remains
higher after RIC HCT. TKI administration prior to HCT can
reduce the relapse to achieve the negative MRD status e
which is the strongest predictor of leukemia recurrence.MRD reduction pre-allograft therefore remains the impor-
tant target for future clinical trials, particularly for patients
who are candidates for RIC HCT.
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Background: Adult patients (pts) with acute lymphoblastic
leukemia (ALL) are stratiﬁed into standard- and high-risk
groups based on WBC count, karyotype and response to
induction chemotherapy. Nevertheless, the standard-risk
group (SR) is heterogeneous with 40%-50% of pts relapse, and
the survival varies from a few months to decades. The role of
immunophenotyping in further sub-stratifying the standard
risk group has not been assessed in adult pts.
Patients and Methods: Out of 161 adult ALL pts diagnosed
and treated at the L/BMT Program of BC between 1989 and
2010, 81 SR pts were separated out based on: WBC50X109/
L (B-ALL) or 100X109/L (T-ALL), absence of adverse cyto-
genetics (i.e. t(9;22), BCR-ABL fusion, complex karyotype (5
abnormalities), t(4;11), t(1;19), low hypodiploid/near trip-
loid), and complete remission (CR) following induction
chemotherapy. The immunophenotype of this group was
reviewed, reanalyzed, and correlated with CR, relapse,
relapse-free survival (RFS), and overall survival (OS). Pts were
treated with a consistent chemotherapy regimen: Induction
consisted of prednisone, vincristine and daunorubicin  L-
asparaginase. A second phase of induction comprised of
cyclophosphamide, cytarabine, methotrexate and mercap-
topurine. Intensiﬁcation was with dexamethasone, vincris-
tine, daunorubicin, cyclophosphamide, cytarabine and
thioguanine. Four cycles of consolidation with cytarabine
and tenoposide were given followed by 2-year maintenance
oral chemotherapy with methotrexate and mercaptopurine.
Results: Eighty-one standard-risk adult ALL pts (62 B-ALL, 19
T-ALL) were identiﬁed, (50 males , 31 females), median age
33 years (16-66). With a median follow up of 30 months (3-
235), 32 pts (40%) relapsed within 1-136 months. The
median OS and RFS were 30 months (3-235) and 26 months
(1-235) respectively. CD13, CD33 and CD117 data was avail-
able in 59, 58 and 50 pts respectively. They were positive in
17 (29%), 13 (22%) and 0 (0%) pts respectively. At least one of
CD13 or 33 or 117 was available in 61, and positive in 25 of
them (41%). Aberrant expression of myeloid antigens was
associated with early relapse (median 8 vs 16 months),
shorter survival (median 11 vs 28 months). OS at 24 months
and 60 months and RFS at 24 months were inferior in ALL
patients expressing myeloid antigens (Table 1).
Conclusion: In adult patients with standard-risk ALL, aber-
rant expression of myeloid antigens indicates early relapse,
